Vascular endothelial growth factor receptor 1-derived HLA-A*2402-restricted peptide epitope (VEGFR1-A24 peptide)

The Vascular endothelial growth factor receptor 1 (VEGFR1)-derived HLA-A*2402-restricted peptide epitope is a specific antigenic fragment used in cancer immunotherapy. It is typically represented by the VEGFR1-1084 peptide, which consists of the amino acid sequence SYGVLLWEI (Mizukami et al., 2008). This peptide is presented on the cell surface by the HLA-A*2402 molecule, a common MHC class I allele in Asian populations (Wada et al., 2010). The primary therapeutic goal of targeting this epitope is to stimulate the production of cytotoxic T lymphocytes (CTLs) that can specifically recognize and destroy VEGFR1-expressing cells. Since VEGFR1 is highly expressed on the vascular endothelial cells of tumor tissues and certain malignant cells, this approach effectively targets tumor angiogenesis and the tumor microenvironment (Masui et al., 2012). Clinical trials have explored its use in various solid tumors, including colorectal, gastric, and pancreatic cancers, often as part of a multi-peptide vaccine regimen. By inducing an immune response against the tumor's blood supply, this target offers a strategy to suppress tumor growth and metastasis.

Other names

VEGFR1-1084 peptideFlt-1-derived peptideVEGFR1 epitopeSYGVLLWEI

Induction of peptide-specific cytotoxic T lymphocytes (CTLs) that recognize and lyse VEGFR1-expressing cells, including tumor-associated endothelial cells and malignant cells, thereby inhibiting angiogenesis and tumor progression.